Product
Ad26/protein preF RSV Vaccine
1 clinical trial
1 indication
Indication
Respiratory Syncytial Virus PreventionClinical trial
A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate Efficacy, Safety, Reactogenicity, and Immunogenicity of an Ad26.RSV.preF-based Vaccine in Japanese Adults Aged 60 Years and Older, and Safety, Reactogenicity, and Immunogenicity of the Vaccine in Japanese Adults Aged 20 to 59 Years at High-risk of RSV DiseaseStatus: Terminated, Estimated PCD: 2023-03-20